For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 49,232 | 31,917* | 39,951 | 43,902 |
| General and administrative | 8,754 | 6,169* | 5,926 | 3,962 |
| Total operating expenses | 57,986 | 38,086 | 45,877 | 47,864 |
| Loss from operations | -57,986 | -38,086* | -45,877 | -47,864 |
| Interest income | 4,776 | 4,689* | 3,648 | 4,042 |
| Other income (gain) | 121 | -52* | 12 | 38 |
| Total other income | 4,897 | 4,637* | 3,660 | 4,080 |
| Net loss | -53,089 | -33,449 | -42,217 | -43,784 |
| Basic EPS | -0.52 | -0.373 | -0.49 | -0.51 |
| Diluted EPS | -0.52 | -0.373 | -0.49 | -0.51 |
| Basic Average Shares | 102,800,098 | 89,788,434 | 85,732,221 | 85,497,426 |
| Diluted Average Shares | 102,800,098 | 89,788,434 | 85,732,221 | 85,497,426 |
Olema Pharmaceuticals, Inc. (OLMA)
Olema Pharmaceuticals, Inc. (OLMA)